Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.
Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 2, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalomyelitis - Overview
Encephalomyelitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalomyelitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalomyelitis - Companies Involved in Therapeutics Development
AIM ImmunoTech Inc
Biovista Inc
Cortene Inc
F. Hoffmann-La Roche Ltd
K-Pax Pharmaceuticals Inc
NLS Pharmaceutics AG
Orion BioScience Inc
Paxmedica Inc
Telesphore Pharma
Trethera Corp
Virios Therapeutics, Inc
Encephalomyelitis - Drug Profiles
(celecoxib + famciclovir) - Drug Profile
Product Description
Mechanism Of Action
CADIT-1031 - Drug Profile
Product Description
Mechanism Of Action
CT-38 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Gene Therapy to Target IL-10, NT-3 and LINGO-1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
JM-4 - Drug Profile
Product Description
Mechanism Of Action
KPAX-002 - Drug Profile
Product Description
Mechanism Of Action
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NLS-4 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ORNx-KI - Drug Profile
Product Description
Mechanism Of Action
History of Events
PAX-101 - Drug Profile
Product Description
Mechanism Of Action
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule for Chronic Fatigue Syndrome - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Encephalomyelitis - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Activate NFE2L2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile
Product Description
Mechanism Of Action
WEHI-345 - Drug Profile
Product Description
Mechanism Of Action
Encephalomyelitis - Dormant Projects
Encephalomyelitis - Product Development Milestones
Featured News & Press Releases
Nov 30, 2021: NLS Pharmaceutics announces preclinical results confirming the potential benefit and safety profile of NLS-4 for circadian rhythm dysregulation and chronic fatigue syndrome in long-covid model
Oct 14, 2021: NLS Pharmaceutics announces preclinical data demonstrating the potential of NLS-4 (Lauflumide) to treat chronic fatigue associated with long-covid
Jan 07, 2021: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Dec 24, 2020: AIM ImmunoTech announces availability of the ME/CFS clinical trial of its drug Ampligen for enrollment to COVID-19 ‘Long Haulers’
Nov 02, 2020: AIM ImmunoTech announces PLOS ONE’s publication of new data analyses showing importance of disease duration on Ampligen’s positive role in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Oct 06, 2020: AIM ImmunoTech announces IRB approval to enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS clinical trial of Ampligen
Jun 15, 2020: AIM ImmunoTech provides update on commercial launch of Ampligen in Argentina for the treatment of chronic fatigue syndrome
Sep 24, 2019: AIM ImmunoTechs Ampligen receives clearance from FDA for exportation to Argentina for the treatment of severe chronic fatigue syndrome
May 06, 2019: Hemispherx links Stanford’s ME/CFS diagnostic to a potential path forward for Ampligen Commercialization
Jan 24, 2019: Hemispherx Biopharmas CEO to present at the 15th Annual NobleConXV Conference
Jan 02, 2019: Hemispherx Biopharma announces advancement in expanded access program for Ampligen in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Dec 19, 2018: Hemispherx Biopharma announces first large Ampligen shipment to a clinical site for use in U.S. Expanded Access Program
Dec 17, 2018: Hemispherx Biopharma announces updated information about ME/CFS expanded access program in the United States
Oct 22, 2018: Hemispherx Outlines Ampligen combination therapy clinical study strategy for the treatment of multiple cancers in letter to stockholders
Sep 18, 2018: Hemispherx to Distribute Second Lot of Ampligen for use in Multiple Indications in Argentina, the United States and Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Encephalomyelitis, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Encephalomyelitis - Pipeline by AIM ImmunoTech Inc, 2022
Encephalomyelitis - Pipeline by Biovista Inc, 2022
Encephalomyelitis - Pipeline by Cortene Inc, 2022
Encephalomyelitis - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, 2022
Encephalomyelitis - Pipeline by NLS Pharmaceutics AG, 2022
Encephalomyelitis - Pipeline by Orion BioScience Inc, 2022
Encephalomyelitis - Pipeline by Paxmedica Inc, 2022
Encephalomyelitis - Pipeline by Telesphore Pharma, 2022
Encephalomyelitis - Pipeline by Trethera Corp, 2022
Encephalomyelitis - Pipeline by Virios Therapeutics, Inc, 2022
Encephalomyelitis - Dormant Projects, 2022
Encephalomyelitis - Dormant Projects, 2022 (Contd..1)
List of Figures
Number of Products under Development for Encephalomyelitis, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
